129 related articles for article (PubMed ID: 34798195)
1. Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy.
Sang J; Gan L; Zou MF; Lin ZJ; Fan RZ; Huang JL; Li W; Tang GH; Yin S
Cancer Lett; 2022 Feb; 526():352-362. PubMed ID: 34798195
[TBL] [Abstract][Full Text] [Related]
2. Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells.
Sang J; Li W; Diao HJ; Fan RZ; Huang JL; Gan L; Zou MF; Tang GH; Yin S
Cancer Lett; 2021 Jul; 509():13-25. PubMed ID: 33836250
[TBL] [Abstract][Full Text] [Related]
3. Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway.
Xu HY; Chen ZW; Hou JC; Du FX; Liu JC
Oncol Rep; 2013 Jan; 29(1):212-8. PubMed ID: 23129237
[TBL] [Abstract][Full Text] [Related]
4. Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells.
Sang J; Liu CK; Liu J; Luo GC; Zheng WJ; Bai Y; Jiang DY; Pu JN; An S; Xu TR
Biochem Pharmacol; 2024 May; 223():116194. PubMed ID: 38583812
[TBL] [Abstract][Full Text] [Related]
5. Eriocalyxin B, a novel autophagy inducer, exerts anti-tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer.
Zhou X; Yue GG; Chan AM; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Biochem Pharmacol; 2017 Oct; 142():58-70. PubMed ID: 28669564
[TBL] [Abstract][Full Text] [Related]
6. Jolkinolide A and Jolkinolide B Inhibit Proliferation of A549 Cells and Activity of Human Umbilical Vein Endothelial Cells.
Shen L; Zhang SQ; Liu L; Sun Y; Wu YX; Xie LP; Liu JC
Med Sci Monit; 2017 Jan; 23():223-237. PubMed ID: 28087861
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway.
Mi S; Xiang G; Yuwen D; Gao J; Guo W; Wu X; Wu X; Sun Y; Su Y; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2016 Nov; 310():78-86. PubMed ID: 27639426
[TBL] [Abstract][Full Text] [Related]
8. Endoplasmic reticulum stress sensitizes human esophageal cancer cell to radiation.
Pang XL; He G; Liu YB; Wang Y; Zhang B
World J Gastroenterol; 2013 Mar; 19(11):1736-48. PubMed ID: 23555162
[TBL] [Abstract][Full Text] [Related]
9. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells.
Dickstein RJ; Nitti G; Dinney CP; Davies BR; Kamat AM; McConkey DJ
Cancer Biol Ther; 2012 Nov; 13(13):1325-38. PubMed ID: 22895070
[TBL] [Abstract][Full Text] [Related]
10. Ampelopsin-induced autophagy protects breast cancer cells from apoptosis through Akt-mTOR pathway via endoplasmic reticulum stress.
Zhou Y; Liang X; Chang H; Shu F; Wu Y; Zhang T; Fu Y; Zhang Q; Zhu JD; Mi M
Cancer Sci; 2014 Oct; 105(10):1279-87. PubMed ID: 25088800
[TBL] [Abstract][Full Text] [Related]
11. Jolkinolide B induces apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway.
Lin Y; Cui H; Xu H; Yue L; Xu H; Jiang L; Liu J
Oncol Rep; 2012 Jun; 27(6):1976-80. PubMed ID: 22426554
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
Guilbert C; Annis MG; Dong Z; Siegel PM; Miller WH; Mann KK
PLoS One; 2013; 8(12):e85995. PubMed ID: 24392034
[TBL] [Abstract][Full Text] [Related]
13. MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J; Yemelyanenko J; Chao X; Klarenbeek S; Opdam M; Malka Y; Hoekman L; Kruger D; Bleijerveld O; Brambillasca CS; Sprengers J; Siteur B; Annunziato S; van Haren MJ; Martin NI; van de Ven M; Peters D; Agami R; Linn SC; Boven E; Altelaar M; Jonkers J; Zingg D; Wessels LFA
J Exp Med; 2023 Nov; 220(11):. PubMed ID: 37642941
[TBL] [Abstract][Full Text] [Related]
14. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
16. Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.
Gao X; Han H
J Cell Biochem; 2018 Jun; 119(6):4967-4974. PubMed ID: 29384225
[TBL] [Abstract][Full Text] [Related]
17. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
[TBL] [Abstract][Full Text] [Related]
18. The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid Models.
Knigin A; Avniel-Polak S; Leibowitz G; Oleinikov K; Gross DJ; Grozinsky-Glasberg S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944946
[TBL] [Abstract][Full Text] [Related]
19. Endoplasmic reticulum stress could induce autophagy and apoptosis and enhance chemotherapy sensitivity in human esophageal cancer EC9706 cells by mediating PI3K/Akt/mTOR signaling pathway.
Zhou F; Li YH; Wang JJ; Pan J; Lu H
Tumour Biol; 2017 Jun; 39(6):1010428317705748. PubMed ID: 28631572
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death.
Makhov P; Golovine K; Teper E; Kutikov A; Mehrazin R; Corcoran A; Tulin A; Uzzo RG; Kolenko VM
Br J Cancer; 2014 Feb; 110(4):899-907. PubMed ID: 24434432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
